It is acknowledged that IL-8-C-X-C motif chemokine receptor 2 (CXCR2) axis powerfully recruits neutrophils and promotes NETs formation.231 However, the clinical trial of anti-IL-8 monoclonal antibody BMS-986253 for COVID-19 has been terminated according to an interim analysis that suggested its ineffectiveness (NCT04347226). This evidence concerns the gene CXCL8 and COVID-19.